Regenerative Medicine Innovation Projects (RMIP) (UT2 - Clinical Trial Not Allowed)
Agency: National Institutes of Health
Assistance Listings
- 93.838 -- Lung Diseases Research
- 93.286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health
- 93.350 -- National Center for Advancing Translational Sciences
- 93.121 -- Oral Diseases and Disorders Research
- 93.242 -- Mental Health Research Grants
- 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
- 93.173 -- Research Related to Deafness and Communication Disorders
- 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research
- 93.233 -- National Center on Sleep Disorders Research
- 93.866 -- Aging Research
- 93.867 -- Vision Research
- 93.839 -- Blood Diseases and Resources Research
- 93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- 93.837 -- Cardiovascular Diseases Research
- 93.856 -- Microbiology and Infectious Diseases Research
- 93.855 -- Allergy and Infectious Diseases Research
- 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research
Archived opportunityLast Updated: May 13, 2026
View version history on Grants.gov
Description
The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (UT2) applications to support small business research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions....
Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness. Toward these ends, the NIH will consider applications for late stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.
Eligibility
Eligible applicants
Business
- Small businesses
Additional information
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grantor contact information
Description
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Documents
No documents are currently available.
Link to additional information
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-033.html
Archived: November 24, 2018
Award
$--
Program Funding
--
Expected awards
$--
Award Minimum
$225,000
Award Maximum
Funding opportunity number:
RFA-HL-18-033
Cost sharing or matching requirement:
No
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
--
Category of Funding Activity:
Health
Food and nutrition
Category Explanation:
--
History
Version:
1
Posted date:
August 1, 2018
Archive date:
November 24, 2018
